These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19497337)

  • 41. The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?
    Shippenberg TS
    Neuropsychopharmacology; 2009 Jan; 34(1):247. PubMed ID: 19079072
    [No Abstract]   [Full Text] [Related]  

  • 42. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological challenges to the endogenous opioid system in affective illness.
    Cohen MR; Pickar D
    J Clin Psychopharmacol; 1981 Jul; 1(4):223-31. PubMed ID: 7028803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3D-pharmacophore identification for kappa-opioid agonists using ligand-based drug-design techniques.
    Yamaotsu N; Hirono S
    Top Curr Chem; 2011; 299():277-307. PubMed ID: 21630511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynorphin activation of kappa opioid receptor reduces neuronal excitability in the paraventricular nucleus of mouse thalamus.
    Chen Z; Tang Y; Tao H; Li C; Zhang X; Liu Y
    Neuropharmacology; 2015 Oct; 97():259-69. PubMed ID: 26056031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
    Schattauer SS; Kuhar JR; Song A; Chavkin C
    Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynorphin, stress, and depression.
    Knoll AT; Carlezon WA
    Brain Res; 2010 Feb; 1314():56-73. PubMed ID: 19782055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychotomimetic effects of kappa opioid receptor agonists.
    White KL; Roth BL
    Biol Psychiatry; 2012 Nov; 72(10):797-8. PubMed ID: 23083945
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction.
    Peart JN; Gross ER; Gross GJ
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):410-5. PubMed ID: 15076225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.
    Carr GV; Bangasser DA; Bethea T; Young M; Valentino RJ; Lucki I
    Neuropsychopharmacology; 2010 Feb; 35(3):752-63. PubMed ID: 19924112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
    Jackson KJ; Jackson A; Carroll FI; Damaj MI
    Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats.
    Mitchell JM; Liang MT; Fields HL
    Psychopharmacology (Berl); 2005 Nov; 182(3):384-92. PubMed ID: 16001119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis.
    Erikson CM; Wei G; Walker BM
    Neuropharmacology; 2018 Sep; 140():162-173. PubMed ID: 30075159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age-dependent regulation of GABA transmission by kappa opioid receptors in the basolateral amygdala of Sprague-Dawley rats.
    Przybysz KR; Werner DF; Diaz MR
    Neuropharmacology; 2017 May; 117():124-133. PubMed ID: 28163104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling.
    Jacobson ML; Wulf HA; Tsuda MC; Browne CA; Lucki I
    Neuropharmacology; 2020 Oct; 177():108254. PubMed ID: 32726598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.
    Cami-Kobeci G; Neal AP; Bradbury FA; Purington LC; Aceto MD; Harris LS; Lewis JW; Traynor JR; Husbands SM
    J Med Chem; 2009 Mar; 52(6):1546-52. PubMed ID: 19253970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.
    Townsend EA
    Psychopharmacology (Berl); 2021 Apr; 238(4):1017-1028. PubMed ID: 33404739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Involvement of kappa-opioid receptors in visceral nociception in mice.
    Larsson MH; Bayati A; Lindström E; Larsson H
    Neurogastroenterol Motil; 2008 Oct; 20(10):1157-64. PubMed ID: 18643891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.